Pembrolizumab (Keytruda®) for the treatment of advanced melanoma by Rothschedl, E. & Nachtnebel, A.
1 LBI-HTA   
Horizon Scanning 
in Oncology 
Pembrolizumab (Keytruda®) 
for the treatment of advanced 
melanoma 
 
 
DSD: Horizon Scanning in Oncology No. 55 
ISSN online 2076-5940 

 Horizon Scanning 
in Oncology 
Pembrolizumab (Keytruda®) 
for the treatment of advanced 
melanoma 
 
Vienna, October 2015 
 Institute for Health Technology Assessment 
Ludwig Boltzmann Gesellschaft  
 
Authors:  Dr. med. Eleen Rothschedl 
Internal review: Dr. med. Anna Nachtnebel, MSc 
External review: Univ.-Prof. Johann Bauer, MBA HCM 
Vorstand der Universitätsklinik für Dermatologie 
Salzburger Landeskliniken – Universitätsklinikum Salzburg 
 
 
 
 
 
 
 
DISCLAIMER 
This technology summary is based on information available at the time of research and on a limited literature search.  
It is not a definitive statement on safety, effectiveness or efficacy and cannot replace professional medical advice nor 
should it be used for commercial purposes. 
The HTA Core Model ® for Rapid Relative Effectiveness for Pharmaceuticals, developed within EUnetHTA 
(www.eunethta.eu), has been utilized when producing the contents and/or structure of this work. A working version 
(unpublished) of V3.0 of the Model was used. Use of the HTA Core Model does not guarantee the accuracy, 
completeness, quality or usefulness of any information or service produced or provided by using the Model 
 
 
 
CONTACT INFORMATION 
Publisher: 
Ludwig Boltzmann Gesellschaft GmbH 
Nußdorferstr. 64, 6 Stock, A-1090 Vienna 
http://hta.lbg.ac.at/page/imprint 
Responsible for Contents: 
Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA)  
Garnisongasse 7/20, A-1090 Vienna 
http://hta.lbg.ac.at/ 
Decision support documents of the LBI-HTA do not appear on a regular basis and serve to publicize  
the research results of the Ludwig Boltzmann Institute of Health Technology Assessments. 
Decision support documents of the LBI-HTA are only available to the public via the Internet at 
„http://eprints.hta.lbg.ac.at“: 
DSD: Horizon Scanning in Oncology No. 55 
ISSN-online: 2076-5940 
http://eprints.hta.lbg.ac.at/view/types/ 
© 2015 LBI-HTA – All rights reserved 
 LBI-HTA | 2015 3 
Table of Contents 
1 Research questions ............................................................................................................................................... 5 
2 Drug description .................................................................................................................................................. 6 
3 Indication .............................................................................................................................................................. 6 
4 Current regulatory status .................................................................................................................................... 7 
5 Burden of disease ................................................................................................................................................. 7 
6 Current treatment ................................................................................................................................................ 9 
7 Evidence ................................................................................................................................................................. 9 
7.1 Efficacy and safety – Phase III studies...................................................................................................... 10 
7.1.1 Efficacy .................................................................................................................................................... 12 
7.1.2 Safety ........................................................................................................................................................ 14 
7.2 Efficacy and safety – further studies ......................................................................................................... 15 
8 Estimated costs ................................................................................................................................................... 17 
9 Ongoing research ................................................................................................................................................ 17 
10 Discussion ........................................................................................................................................................... 18 
11 References ............................................................................................................................................................ 22 
 
 
List of Tables 
Table 1: Summary of KEYNOTE-0006 trial and patient characteristics .................................................................... 10 
Table 2: Efficacy results for KEYNOTE-006 .................................................................................................................. 13 
Table 3: Adverse events in the as-treated population ..................................................................................................... 15 
 
 

Pembrolizumab (Keytruda®) for the treatment of advanced melanoma 
LBI-HTA | 2015 5 
1 Research questions 
The HTA Core Model® for Rapid Relative Effectiveness Assessment of Phar-
maceuticals was used for structuring this report [1]. The Model organises 
HTA information according to pre-defined generic research questions. Based 
on these generic questions, the following research questions were answered 
in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is pembrolizumab? 
A0020 For which indications has pembrolizumab received marketing authorisation? 
A0021 What is the reimbursement status of pembrolizumab? 
A0022 Who manufactures pembrolizumab? 
Health problem and Current Use 
A0002 What is melanoma? 
A0003 What are the known risk factors for melanoma? 
A0004 What is the natural course of melanoma? 
A0005 What are the symptoms and the burden of melanoma for the patient? 
A0006 What are the consequences of melanoma for the society? 
A0024 How is melanoma currently diagnosed according to published guidelines and in practice? 
A0025 How is melanoma currently managed according to published guidelines and in practice? 
A0007 What is the target population in this assessment? 
A0023 How many people belong to the target population? 
Clinical Effectiveness 
D0001 What is the expected beneficial effect of pembrolizumab on mortality? 
D0005 How does pembrolizumab affect symptoms and findings (severity, frequency) of advanced 
melanoma? 
D0006 How does pembrolizumab affect progression (or recurrence) of advanced melanoma? 
D0011 What is the effect of pembrolizumab on patients’ body functions? 
D0012 What is the effect of pembrolizumab on generic health-related quality of life? 
D0013 What is the effect of pembrolizumab on disease-specific quality of life? 
Safety 
C0008 How safe is pembrolizumab in relation to the comparator? 
C0002 Are the harms related to dosage or frequency of applying pembrolizumab? 
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2 Drug description 
Generic/Brand name/ATC code:  
Pembrolizumab/Keytruda®/L01XC18 
 
B0001: What is pembrolizumab? 
Pembrolizumab (Keytruda®) is a humanised monoclonal anti-programmed cell 
death-1 (PD-1) antibody (lgG4/kappa isotype with a stabilising sequence al-
teration in the Fc region), which is produced in Chinese hamster ovary cells 
by recombinant DNA technology [2]. It binds to an inhibitory signalling re-
ceptor (PD-1) on the surface of activated T cells and blocks the binding to 
and activation of PD-1 by its ligands, which causes the activation of T-cell-
mediated immune responses against tumour cells. The activation of PD-1 
negatively regulates the activation of T cells; furthermore it plays an im-
portant role in tumour evasion from host immunity [3]. 
The recommended dose of pembrolizumab is 2 mg/kg administered as an in-
travenous (IV) infusion over 30 minutes every three weeks; treatment should 
be continued until disease progression or unacceptable toxicity. In case of 
atypical responses, such as an initial transient increase in tumour size or small 
new lesions within the first few months followed by tumour shrinkage, it is 
recommended to continue treatment for clinically stable patients with initial 
evidence of disease progression until disease progression gets confirmed [2]. 
 
A0022: Who manufactures pembrolizumab? 
Merck Sharp & Dohme 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Pembrolizumab monotherapy is indicated for the treatment of adult patients 
with advanced (unresectable or metastatic) melanoma [2].  
 
 
 
  
anti-PD-1 antibody 
2 mg/kg administered IV 
every 3 weeks 
for patients with 
advanced melanoma 
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4 Current regulatory status 
A0020: For which indications has pembrolizumab received  
marketing authorisation? 
The EMA granted marketing authorisation for Keytruda® as monotherapy 
for the treatment of advanced (unresectable or metastatic) melanoma in adults 
on 17 July 2015. 
The FDA initially granted accelerated approval of Keytruda® in September 
2014, for patients with advanced or unresectable melanoma no longer re-
sponding to other drugs [4]. According to the label approved on 19 June 2015 
[5], pembrolizumab is indicated in patients with unresectable or metastatic 
melanoma and disease progression following ipilimumab and, if BRAF (pro-
to-oncogene B-Raf) V600 mutation-positive, a BRAF inhibitor. This indica-
tion is also approved under accelerated approval and is based on tumour re-
sponse rate and durability of response, whilst an improvement in survival or 
disease-related symptoms has not yet been established. 
 
 
 
5 Burden of disease 
A0002: What is melanoma? 
Melanoma is a skin cancer which starts in the melanocytes. In men, it most 
commonly starts on the trunk (chest and back); in women, most common sites 
are the legs.  
 
A0004: What is the natural course of melanoma? 
If melanoma is not detected and cured in early stages, it can spread to other 
parts of the body [6]. The outcome of melanoma depends on the stage at 
presentation; it is estimated that 82-85% of patients present with localised 
disease, 10-13% with regional disease and 2-5% with distant metastatic disease 
[7].  
 
A0006: What are the consequences of melanoma for the society? 
A0023: How many people belong to the target population? 
In Austria, the incidence of malignant melanoma is 12.2 per 100,000 persons 
per year; in 2011, 1,551 persons were newly diagnosed with malignant mela-
noma [8]. However, this number might underestimate the actual incidence 
due to different reporting structures in Austrian provinces. Age standardised 
incidence data from other European Countries are for example 26.8 per 
100,000 in Switzerland and 26.6 per 100,000 in Norway [9]. In Austria, until 
2030, a significant increase in incidence and mortality is expected; the num-
ber of newly diagnosed disease is expected to increase by 92% in men and 
45% in women [10]. 
approved by the EMA 
FDA granted  
accelerated approval 
definition of disease 
outcome depends on the 
stage at presentation 
incidence rate  
in Austria:  
12.2 per 100,000 persons 
per year 
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The median age at diagnosis of melanoma is 63 years; it is most frequently 
diagnosed among patients aged 55 to 64 years. 91.5 % of melanoma patients 
survive 5 years [11]. In Austria, melanoma mortality rate is 2.2 per 100,000 
persons per year [8].  
 
A0005: What are the symptoms and the burden of melanoma for the patient? 
Warning signs of melanoma are changes in the size, shape or colour of moles 
or other skin lesions. Furthermore, the appearance of a new growth on the 
skin or a sore that does not heal represent warning signs [12].  
 
A0024: How is melanoma currently diagnosed according  
to published guidelines and in practice? 
In case of suspicious lesions, a biopsy should be performed [13]. Therefore, 
an excisional biopsy (elliptical, punch or saucerization) with 1-3 mm marginal 
is preferred and wider marginal should be avoided to permit accurate subse-
quent lymphatic mapping [7].Microstaging should be conducted by an expe-
rienced pathologist [13]. 
Melanomas are classified according to the TNM classification system (T = 
primary tumour, N = regional lymph node, M = distant metastasis). The only 
internationally accepted classification system for melanoma is the revised 
American Joint Committee on Cancer (AJCC) staging system, which is based 
on the TNM system and includes sentinel node staging [14]. 
 
A0003: What are the known risk factors for melanoma? 
Risk factors for the development of melanoma include [15]: 
 fair skin (that burns easily) 
 high lifetime exposure to natural or artificial sunlight 
 a history of blistering sunburns, particularly at a young age 
 many common moles 
 a history (personal or family) of dysplastic nevi or melanoma 
 being white. 
 
 
  
warning signs 
diagnosis 
AJCC classification 
system 
risk factors 
Pembrolizumab (Keytruda®) for the treatment of advanced melanoma 
LBI-HTA | 2015 9 
6 Current treatment 
A0025: How is melanoma currently managed according to published guide-
lines and in practice? 
For the treatment of systemic metastatic melanoma (stage IV), the European 
Society for Medical Oncology (ESMO) recommends [14]: 
 In patients with metastatic melanoma, metastasis or the primary tu-
mour should be screened for detection of BRAF V600 mutation. For 
the first- and second-line setting, different treatment options exist for 
all patients, including anti-PD-1 antibodies (nivolumab) and ipili-
mumab, an anti-CTLA4 antibody. Pembrolizumab has already been 
added to this recommendation as well. For patients with BRAF-mutant 
melanoma, BRAF inhibitors such as vemurafenib, encorafenib and 
dabrafenib are available in combination with MEK1 inhibitors (bi-
nimetinib, cobimetinib and trametinib) (II, B). 
 Cytotoxic drugs which showed modest activity (i.e. DTIC or temozol-
omide) may be administered if clinical trials or the approved new tar-
geted compounds are not available (II, C).  
 Multi-agent polychemotherapy (containing paclitaxel and carboplatin 
or cisplatin, vindesine and dacarbazine) may provide mostly short-
lived partial responses and/or stabilisation of disease in a meaningful 
number of patients with aggressive metastatic disease. 
For patients with metastatic stage IV melanoma, multidisciplinary tumour 
board consultation is mandatory [14, 16]. 
 
 
 
7 Evidence 
A literature search was conducted on 20 August 2015 in four databases: the 
Cochrane Library, CRD Database, Embase and Medline. Search terms were 
“Pembrolizumab”, “Keytruda”, “Lambrolizumab”, “mk-3475” and “Melano-
ma”. Also, the manufacturer was contacted but did not submit any further 
evidence.  
Overall, 199 references were identified. Included in this report are: 
 1 phase III study, assessing pembrolizumab versus ipilimumab in  
advanced melanoma [17, 18] 
 1 randomised dose-comparison study [19], comparing two different 
dosages of pembrolizumab in advanced melanoma 
 1 randomised, controlled phase II trial [20], evaluating pembrolizumab 
versus investigator-choice chemotherapy in patients with advanced 
melanoma. 
 
                                                             
1 MEK = mitogen-activated protein 
recommendations  
for treatment 
systematic search in  
4 databases 
included:  
1 phase III study,  
1 dose-comparison study, 
1 phase II study 
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7.1 Efficacy and safety – Phase III studies 
KEYNOTE-006 [17, 18] is an international, randomised, controlled, open-
label phase III study comparing two different dosing regimens of pembroli-
zumab to ipilimumab in patients with advanced melanoma. A total of 834 
patients were randomly assigned in a 1:1:1 ratio to receive pembrolizumab at 
a dose of 10 mg/kg either every 2 weeks or every 3 weeks, or four cycles of 
ipilimumab at a dose of 3 mg/kg every 3 weeks. Enrolled patients had histo-
logically confirmed unresectable stage III or IV melanoma and had received 
no more than one previous systemic therapy for advanced disease; 65.6% 
(pembrolizumab every 2 weeks), 66.8% (pembrolizumab every 3 weeks) and 
65.1% (ipilimumab) of patients had received no prior line of therapy. In pa-
tients who had received prior systemic therapy, chemotherapy, immunothera-
py or a BRAF or MEK inhibitor (or both) were administered. Patients were 
excluded if they had received previous therapy with cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) or 
programmed death ligand (PD-L1) inhibitors. More than two thirds of pa-
tients of each group had an Eastern Cooperative Oncology Group (ECOG) 
performance status of 0 and metastasis stage M1c. 80.6%, 79.8% and 80.9% 
of patients had PD-L1-positive tumour tissue samples and BRAF V600 muta-
tions were detected in 35.1%, 35.0% and 38.5% of patients receiving pembro-
lizumab every 2 or 3 weeks or ipilimumab respectively. A detailed description 
of KEYNOTE-006 including patient characteristics can be found in Table 1. 
The median duration of follow-up at the time of data cut-off was 7.9 months, 
ranging from 6.1 to 11.5 months; the mean duration of exposure was 164 days 
(pembrolizumab every 2 weeks), 151 days (pembrolizumab every 3 weeks) and 
50 days (ipilimumab group). Due to the superior overall survival (OS) results 
of the two pembrolizumab groups over the ipilimumab group results, the da-
ta and safety monitoring committee recommended to stop the study early and 
give patients of the ipilimumab group the option to receive pembrolizumab.  
Table 1: Summary of KEYNOTE-0006 trial and patient characteristics 
Study title  
Pembrolizumab versus ipilimumab in advanced melanoma [17, 18] 
Study identifier NCT01866319, EudraCT Number 2012-004907-10, KEYNOTE-006 
Design Randomised, controlled, international phase III study 
Duration  Enrolment: 2013-09-18 to 2014-03-03 
Median follow-up (at the time of data cut-off): 7.9 months (range: 6.1 to 11.5) 
Cut-off dates for analyses: 2014-09-03 (first interim analysis),  
2015-03-03 (second interim analysis) 
Hypothesis Superiority  
The Kaplan-Meier method was used to calculate estimates of PFS and OS.  
Treatment differences for PFS and OS were assessed by means of the stratified log-rank test.  
HRs and associated 95% CIs were assessed with the use of a stratified Cox proportional-hazards 
model with Efron’s method of handling ties.  
Response rates in the study groups were compared by the stratified Miettinen and Nurminen method. 
Funding Merck Sharp & Dohme 
Treatment 
groups 
Intervention 
(n=279) 
Pembrolizumab 10 mg/kg (IV during a 30-minute period) every 2 weeks 
Intervention 
(n=277) 
Pembrolizumab 10 mg/kg (IV during a 30-minute period) every 3 weeks 
Control 
(n=278) 
Ipilimumab 3 mg/kg (IV during a 90-minute period) every 3 weeks for 4 cycles 
KEYNOTE-006:  
a randomised phase III 
study in 834 patients 
 
 
comparison of  
2 different dosages of 
pembrolizumab to 
ipilimumab 
mean duration of 
exposure:  
50–164 days 
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Endpoints and 
definitions 
Progression-free 
survival 
(primary endpoint) 
PFS Defined as the time from randomisation to documented disease 
progression according to RECIST or death from any cause 
Overall survival 
(primary endpoint) 
OS Defined as the time from randomisation to death from any cause 
Objective  
response rate  
ORR Defined as the percentage of patients with complete or partial 
response according to RECIST 
Duration of 
response 
DOR Defined as the time from the first documented response to 
radiologic progression according to RECIST 
Safety - - 
Results and analysis 
Analysis  
description 
Efficacy was assessed in the intention-to-treat population. 
Safety was assessed in the as-treated population. 
Analysis  
population 
Inclusion  Age ≥ 18 years 
 Histologically confirmed, unresectable stage III or IV melanoma 
 No more than one previous systemic therapy for advanced disease 
 Known BRAF V600 mutational status; previous BRAF inhibitor therapy 
was not required for patients with normal LDH levels 
 No clinically significant tumour-related symptoms or evidence of  
rapidly progressive disease 
 ECOG performance status 0 or 1 
 Provision of a tumour sample adequate for assessing PD-L1 expression 
Exclusion  Previous therapy with CTLA-4, PD-1, or PD-L1 inhibitors  
 Patients who had ocular melanoma, active brain metastases,  
or a history of serious autoimmune disease 
Characteristics  Pembrolizumab 
every 2 weeks 
Pembrolizumab 
every 3 weeks 
 
Ipilimumab 
Median age  
(range), years 
61 
(18–89) 
63 
(22–89) 
62 
(18–88) 
Male sex, % 57.7 62.8 58.3 
ECOG  
performance status, % 
1 
2 
 
 
70.3 
29.7 
 
 
68.2 
31.8 
 
 
67.6 
32.4 
Elevated baseline  
LDH level, % 
 
29.0 
 
35.4 
 
32.7 
PD-L1-positive tumour, % 80.6 79.8 80.9 
BRAF V600 mutation, % 35.1 35.0 38.5 
Line of previous  
systemic therapy, % 
0 
1 
 
 
65.6 
34.4 
 
 
66.8 
32.9 
 
 
65.1 
34.9 
Type of previous  
systemic therapy, % 
Chemotherapy 
Immunotherapy 
BRAF or MEK  
inhibitor or both 
 
 
 
12.9 
2.9 
17.9 
 
 
 
14.8 
2.5 
16.2 
 
 
 
10.4 
4.3 
20.1 
Abbreviations: BRAF = proto-oncogene B-Raf, CI = confidence interval, CTLA-4 = cytotoxic T-lymphocyte-associated protein 4, 
ECOG = Eastern Cooperative Oncology Group, IV = intravenous, LDH = lactate dehydrogenase, MEK = mitogen-activated 
protein, NR = not reported, ORR = objective response rate, OS = overall survival, PD-1 = programmed cell death protein 1, 
PD-L1 = programmed death ligand 1, PFS = progression-free survival, RECIST = Response Evaluation Criteria In Solid 
Tumours 
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7.1.1 Efficacy 
D0006: How does pembrolizumab affect progression (or recurrence)  
of advanced melanoma? 
The primary endpoint, progression-free survival (PFS), was significantly im-
proved in both pembrolizumab groups compared to the ipilimumab group. 
The estimated 6-month PFS rates were 47.3% (pembrolizumab every 2 weeks), 
46.4% (pembrolizumab every 3 weeks) and 26.5% (ipilimumab group). Me-
dian estimates of PFS were 5.5 months (95% CI2 3.4-6.9), 4.1 months (95% 
CI 2.9-6.9) and 2.8 months (95% CI 2.8-2.9) in patients receiving pembroli-
zumab every 2 weeks, every 3 weeks and in patients receiving ipilimumab 
respectively. The hazard ratios (HR) for disease progression for pembroli-
zumab compared to ipilimumab were 0.58 (95% CI 0.46-0.72); p<0.001) in 
patients receiving pembrolizumab every 2 weeks and 0.58 (95% CI 0.47-0.72; 
p<0.001) in patients receiving the 3-week regimen. The PFS improvement in 
both pembrolizumab groups over the ipilimumab group was reported from 
all prespecified subgroups and the benefit was also observed in both PD-L1-
positive and PD-L1-negative subgroups.  
 
D0001: What is the expected beneficial effect of  
pembrolizumab on mortality? 
Estimated 12-month survival rates were 74.1% (pembrolizumab every 2 weeks), 
68.4% (pembrolizumab every 3 weeks) and 58.2% (ipilimumab group); HR for 
death as compared with the ipilimumab group was 0.63 (95% CI 0.47-0.83; 
p<0.0005) for patients receiving pembrolizumab every 2 weeks and 0.69 (95% 
CI 0.52-0.90; p=0.0036) for patients receiving the 3-week regimen. Median OS 
was not reached in any of the three groups. The benefit in OS of pembroli-
zumab over ipilimumab was reported from all subgroups, with the exception 
of patients with PD-L1-negative tumours (HRs were 0.91 in patients receiv-
ing the 2-week regimen and 1.02 in patients receiving the 3-week regimen, as 
compared with ipilimumab). 
 
D0005: How does pembrolizumab affect symptoms and findings  
(severity, frequency) of advanced melanoma? 
Response rates were 33.7% (pembrolizumab every 2 weeks), 32.9% (pembroli-
zumab every 3 weeks) and 11.9% (ipilimumab group); patients achieved com-
plete response rates of 5.0%, 6.1% and 1.4% receiving pembrolizumab every 
2 or 3 weeks or ipilimumab respectively. The median duration of response was 
not reached in any group; median times to response were 86 days, 85 days 
and 87 days in patients receiving the pembrolizumab 2-week regimen, 3-week 
regimen or receiving ipilimumab respectively. 
 
D0011: What is the effect of pembrolizumab on patients’ body functions? 
D0012: What is the effect of pembrolizumab on generic  
health-related quality of life? 
  
                                                             
2 CI = confidence interval 
primary endpoint: 
progression-free 
survival 
OS benefit of 
pembrolizumab over 
ipilimumab 
response rate improved 
with pembrolizumab 
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D0013: What is the effect of pembrolizumab on  
disease-specific quality of life? 
No evidence was found to answer the research questions concerning the body 
functions and the quality-of-life of patients. 
Table 2: Efficacy results for KEYNOTE-006 
Descriptive 
statistics and 
estimated 
variability3 
 
Treatment group 
Pembrolizumab 
every 2 weeks 
Pembrolizumab  
every 3 weeks 
 
Ipilimumab 
Number of subjects 279 277 278 
PFS median (95% CI), months 5.5 (3.4–6.9) 4.1 (2.9–6.9) 2.8 (2.8–2.9) 
6-month PFS rate, % 47.3 46.4 26.5 
12-month OS rate, % 74.1 68.4 58.2 
Response rate, % 
CR 
PR 
Stable disease 
33.7 
5.0 
28.7 
13.3 
32.9 
6.1 
26.7 
14.1 
11.9 
1.4 
10.4 
16.5 
Ongoing responses, (%) 89.4 96.7 87.9 
Median time to response (range), 
weeks 
86 (32–212) 85 (36–251) 87 (80–250) 
Median duration of response (range), 
months 
25 (42+ to 251) Not reached  
(42+ to 246+) 
Not reached  
(33+ to 239+) 
Effect estimate 
per comparison 
 
Comparison groups 
 2-week regimen  
vs. ipilimumab 
3-week regimen  
vs. ipilimumab 
PFS HR 0.58 0.58 
95% CI 0.46–0.72 0.47–0.72 
P value <0.001 <0.001 
OS HR 0.63 0.69 
95% CI 0.47–0.83 0.52–0.90 
P value <0.0005 0.0036 
Response rates Estimated 
difference 
16.1 17.2 
95% CI 7.8–24.5 9.5–25.6 
P value <0.001 <0.001 
Abbreviations: CI = confidence interval, CR = complete response, HR = hazard ratio, OS = overall survival,  
PFS = progression-free survival, PR = partial response  
 
 
  
                                                             
3 All data are taken from the first interim analysis except those for overall survival, 
which are taken from the second interim analysis.   
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7.1.2 Safety 
C0008: How safe is pembrolizumab in relation to the comparator? 
C0002: Are the harms related to dosage or frequency of  
applying pembrolizumab? 
Adverse events (AEs) of any grade related to treatment were reported from 
79.5% (pembrolizumab every 2 weeks), 72.9% (pembrolizumab every 3 weeks) 
and 73.0% (ipilimumab group) of patients. Most common in the pembroli-
zumab groups were fatigue, diarrhoea, rash and pruritus. In the ipilimumab 
group, pruritus, diarrhoea, fatigue and rash occurred most frequently.  
Concerning different dosages, 37.8% of patients receiving pembrolizumab 
every 2 weeks and 33.2% of patients receiving pembrolizumab every 3 weeks 
experienced a grade 3, 4 or 5 event. In patients of the ipilimumab group, a 
grade 3, 4 or 5 event occurred in 36.7% of patients. 
Treatment-related grade 3-5 AEs occurred in 13.3% of patients receiving pem-
brolizumab every 2 weeks, in 10.1% of patients receiving pembrolizumab 
every 3 weeks and in 19.9% of patients receiving ipilimumab. Median time 
to onset of first grade 3, 4 or 5 AE was 59.0 days (pembrolizumab every 2 
weeks), 64.0 days (pembrolizumab every 3 weeks) and 39.5 days (ipilimumab 
group). HR was 0.59 (95% CI, 0.43-0.80, p<0.001) comparing the 2-week-
regimen to ipilimumab and 0.53 (95%CI 0.38-0.72, p<0.001) for the 3-week-
regimen versus ipilimumab. The similar safety profiles of the two different 
dosages of pembrolizumab as well as the safety profile of ipilimumab are 
shown in Table 3. Treatment-related AEs led to permanent discontinuation 
of a study drug in 4.0% (pembrolizumab every 2 weeks), 6.9% (pembroli-
zumab every 3 weeks) and 9.4% (ipilimumab group) of patients.  
The most common AEs of special interest4 among the patients of the pem-
brolizumab groups were hypothyroidism and hyperthyroidism; grade 3 to 4 
AEs reported from more than 1% of these patient groups were colitis and 
hepatitis. In the ipilimumab group, the most frequent AE of special interest 
was colitis; grade 3 to 4 AEs occurring in more than 1% of these patients 
were colitis and inflammation of the pituitary gland. 
 
 
  
                                                             
4 On the basis of the likely autoimmune or immune-related mechanism 
frequency of AEs 
treatment-related AEs 
AEs of particular 
interest 
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Table 3: Adverse events in the as-treated population 
Adverse event (according 
to NCI-CTC version 4.0) 
Pembrolizumab  
every 2 weeks (n=278) 
Pembrolizumab  
every 3 weeks (n=277) 
Ipilimumab  
(n=256) 
 Any grade Grade 3–5 Any grade Grade 3–5 Any grade Grade 3–5 
Related to treatment 
Any 221 (79.5) 37 (13.3) 202 (72.9) 28 (10.1) 187 (73.0) 51 (19.9) 
Occurring in 10% of patients in any study group 
Fatigue 58 (20.9) 0 53 (19.1) 1 (0.4) 39 (15.2) 3 (1.2) 
Diarrhoea 47 (16.9) 7 (2.5) 40 (14.4) 3 (1.1) 58 (22.7) 8 (3.1) 
Rash 41 (14.7) 0 37 (13.4) 0 37 (14.5) 2 (0.8) 
Pruritus 40 (14.4) 0 39 (14.1) 0 65 (25.4) 1 (0.4) 
Asthenia 32 (11.5) 1 (0.4) 31 (11.2) 0 16 (6.3) 2 (0.8) 
Nausea 28 (10.1) 0 31 (11.2) 1 (0.4) 22 (8.6) 1 (0.4) 
Arthralgia 26 (9.4) 0 32 (11.6) 1 (0.4) 13 (5.1) 2 (0.8) 
Vitiligo 25 (9.0) 0 31 (11.2) 0 4 (1.6) 0 
Adverse event of special interest 
Hypothyroidism 28 (10.1) 1 (0.4) 24 (8.7) 0 5 (2.0) 0 
Hyperthyroidism 18 (6.5) 0 9 (3.2) 0 6 (2.3) 1 (0.4) 
Colitis 5 (1.8) 4 (1.4) 10 (3.6) 7 (2.5) 21 (8.2) 18 (7.0) 
Hepatitis 3 (1.1) 3 (1.1) 5 (1.8) 5 (1.8) 3 (1.2) 1 (0.4) 
Hypophysitis 1 (0.4) 1 (0.4) 2 (0.7) 1 (0.4) 6 (2.3) 4 (1.6) 
Pneumonitis 1 (0.4) 0 5 (1.8) 1 (0.4) 1 (0.4) 1 (0.4) 
Type 1 diabetes mellitus 1 (0.4) 1 (0.4) 1 (0.4) 1 (0.4) 0 0 
Uveitis 1 (0.4) 0 3 (1.1) 0 0 0 
Myositis 0 0 2 (0.7) 0 1 (0.4) 0 
Nephritis 0 0 1 (0.4) 0 1 (0.4) 1 (0.4) 
Abbreviation: NCI-CTC = National Cancer Institute Common Terminology Criteria for Adverse Events 
 
 
7.2 Efficacy and safety – further studies 
A randomised dose-comparison study [19] was conducted as an expansion co-
hort of KEYNOTE-001 (a large phase I study evaluating pembrolizumab for 
the treatment of non-small-cell lung cancer) to assess the clinical benefit of 
pembrolizumab. Included were 173 patients with ipilimumab-refractory mel-
anoma defined as disease progression after at least 2 doses of ipilimumab 
(3 mg/kg or higher administered every 3 weeks) and within 24 weeks of the 
last dose of ipilimumab. The majority of patients (82%) had no BRAF muta-
tion. With 72% of patients having received at least two and with 35% of pa-
tients having received more than 3 prior lines of therapy, patients were heav-
ily pretreated. All patients had been treated with ipilimumab but other types 
of treatment comprised immunotherapy (excluding ipilimumab), chemother-
apy, or BRAF or MEK inhibitors (or both). A total of 173 patients were as-
signed to receive pembrolizumab either at a dose of 2 mg/kg or 10 mg/kg 
every 3 weeks until disease progression, intolerable toxicity or consent with-
drawal. Median follow-up was 8 months; the median number of days from first  
dose-comparison study: 
2 mg/kg versus 10 mg/kg 
 
 
 
pretreated patients 
Horizon Scanning in Oncology 
16 LBI-HTA | 2015 
to last pembrolizumab dose was 188.0 days in patients who received pembroli-
zumab 2 mg/kg and 185.5 days in patients of the pembrolizumab 10 mg/kg 
group. The overall response rate (ORR), which was the primary endpoint of 
the study, was 26% in both groups. Median PFS was 22 weeks (95% CI 12-36) 
in the pembrolizumab 2 mg/kg group and 14 weeks (95% CI 12-24) in the 
pembrolizumab 10 mg/kg group when measured by an independent central 
review; this differs from the results assessed by the investigator using immune-
related response criteria: here, median PFS was 31 weeks (pembrolizumab 
2 mg/kg group) versus 35 weeks (10 mg/kg group). The Kaplan-Meier esti-
mated OS at 1 year was 58% (95% CI 47-68) in patients receiving pembroli-
zumab at a dose of 2 mg/kg and 63% (51-72) in patients of the pembrolizumab 
10 mg/kg group. 82% of patients in each group had drug-related AEs but 
drug-related grade 3 or 4 adverse events occurred in 20 (12%) patients. Seri-
ous drug-related AEs were reported from 8% and 1% of patients receiving 
2 mg/kg and 10 mg/kg of pembrolizumab respectively. Serious immune-re-
lated AEs occurred in 3% and 1% and immune-related grade 3 or 4 AEs in 
1% and 2% of patients respectively. The most common grade 3 or 4 drug-
related AE occurring in one or more patients was fatigue.   
KEYNOTE-002 [20] is a randomised, controlled phase II trial, comparing 
two different doses of pembrolizumab with investigator-choice chemothera-
py in overall 540 patients. Enrolled patients had unresectable stage III or IV 
melanoma not amenable to local therapy, confirmed disease progression with-
in 24 weeks of the last ipilimumab dose and previous BRAF or MEK inhibi-
tor therapy (or both). 77% of patients had BRAF V600 wild-type status. Ap-
proximately one third of patients had more than 3 prior lines of therapy, in-
cluding ipilimumab, interleukin 2, immunotherapy (excluding ipilimumab 
and interleukin 2), chemotherapy and BRAF or MEK inhibitor. A total of 540 
patients were assigned in a 1:1:1 ratio to receive pembrolizumab 2 mg/kg, 
pembrolizumab 10 mg/kg (both administered IV every 3 weeks) or investiga-
tor-choice chemotherapy, including paclitaxel plus carboplatin, paclitaxel, 
carboplatin, dacarbazine or oral temzolomide. Median follow-up duration was 
10 months; median time of treatment was 113 days (pembrolizumab 2 mg/kg 
group), 145 days (pembrolizumab 10 mg/kg group) and 61 days (chemother-
apy group).  
PFS, the primary endpoint at the second interim analysis, was significantly 
improved (based on 410 PFS events): HRs, compared to chemotherapy were 
0.57 (95% CI 0.45-0.73) in patients receiving 2 mg/kg and 0.50 (95% CI 0.39-
0.64) in patients receiving 10 mg/kg. By 6 months, 34% (pembrolizumab 2 mg/ 
kg), 38% (pembrolizumab 10 mg/kg) and 16% (chemotherapy) of patients 
were progression free. Median PFS was 2.9 (2.8-3.8) months in patients who 
received pembrolizumab 2 mg/kg, 2.9 (2.8-4.7) months in patients receiving 
10 mg/kg and 2.7 (2.5-2.8) months in patients of the chemotherapy group. 
A response was achieved in 21%, 25% and 4% of patients receiving pem-
brolizumab 2 mg/kg, 10 mg/kg or chemotherapy respectively. Median dura-
tion of response was not reached in both pembrolizumab groups, whereas 
patients in the chemotherapy group had a median duration of response of 37 
weeks. The change from baseline to week 12 in the global health status and 
quality-of-life score of the EORTC QLQ-30 questionnaire were exploratory 
endpoints. Between the 2 mg/kg pembrolizumab group and chemotherapy 
group and the 10 mg/kg pembrolizumab group and the chemotherapy group, 
the least squares mean change differed significantly (6.53, 95% CI 1.53-11.53, 
p = 0.011 and 6.57, 1.65-11.50, p = 0.009 respectively). At week 12, the glob-
al health status quality-of-life score deteriorated by 10 points or more in ap-
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proximately 7% to 12% fewer patients receiving pembrolizumab than in pa-
tients receiving chemotherapy. Treatment-related AEs of grade 3-4 were re-
ported from 11% (pembrolizumab 2 mg/kg), 14% (pembrolizumab 10 mg/kg) 
and 26% (chemotherapy group) of patients, most common in the pembroli-
zumab groups was fatigue. The occurrence of serious treatment-related AEs 
was similar in all 3 treatment groups; most frequent in both pembrolizumab 
groups were diarrhoea and pneumonitis (1% of patients in each group). 
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of pembrolizumab? 
In patients with advanced (unresectable or metastatic) melanoma, the recom-
mended dose of pembrolizumab is 2 mg/kg administered every 3 weeks [2]. 
In Austria, pembrolizumab (Keytruda®) is available as powder for solution 
for injection 50 mg at € 1,812.55 [21]. Assuming an average body weight of 
70 kg, 3 vials of pembrolizumab would be needed, costs would therefore 
amount to € 5,437.65 per treatment. For one year of pembrolizumab treat-
ment, overall costs of € 92,440 would incur. 
 
 
 
9 Ongoing research 
In September 2015, a search in www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu was conducted. The following phase III trials, 
evaluating the use of pembrolizumab in melanoma, were identified: 
 NCT02506153: A randomised phase III trial comparing high-dose in-
terferon to pembrolizumab in patients with high-risk resected mela-
noma. The estimated primary completion date is June 2020. 
 NCT02362594, EudraCT number 2014-004944-37, MK-3475-054, KEY-
NOTE-054): A randomised, double-blind phase III trial by the EORTC5 
Melanoma Group, evaluating adjuvant immunotherapy with pembro-
lizumab versus placebo after complete resection of high-risk stage III 
melanoma. The estimated study completion date is September 2023. 
 NCT02263508, MASTERKEY-265: A multicentre, open-label phase 
1b/3 trial of talimogene laherparepvec in combination with pembroli-
zumab (MK-3475) for the treatment of unresected stage IIIB to IVM1c 
melanoma. Estimated study completion date is February 2023. 
 NCT02083484: An expanded access programme of MK-3475 in meta-
static melanoma patients with limited to no treatment options. 
 
                                                             
5 EORTC = European Organization for Research and Treatment of Cancer 
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Pembrolizumab is currently investigated in numerous phase II trials, assessing 
the use in different treatment lines and combinations with other agents for 
the treatment of melanoma and in different types of cancer, for example:  
 pembrolizumab versus chemotherapy in advanced melanoma 
 neoadjuvant pembrolizumab for unresectable stage III and 
unresectable stage IV melanoma 
 double-immune suppression blockade by combining a CSF1R 
Inhibitor (PLX3397) with pembrolizumab for the treatment of 
advanced melanoma and other solid tumours 
 pembrolizumab in children with advanced melanoma or a  
PD-L1-positive advanced, relapsed or refractory solid tumour or 
lymphoma (KEYNOTE-051) 
 pembrolizumab with pegylated interferon alfa-2b (PEG-IFN) and 
pembrolizumab with ipilimumab in patients with advanced melanoma 
and renal cell carcinoma (KEYNOTE-029) 
 pembrolizumab in conjunction with lymphodepletion, TIL (T-cells) 
and high- or low-dose interleukin-2 in patients with metastatic 
melanoma 
 study of enhancing pembrolizumab responses in melanoma through 
intratumoural pIL-12 electroporation 
 pembrolizumab in combination with trametinib and dabrafenib in 
patients with advanced melanoma 
 combination of pembrolizumab and stereotactic body radiotherapy  
in patients with metastatic melanoma or NSCLC 
 in patients with advanced sarcoma 
 pembrolizumab for the treatment of advanced uveal melanoma. 
 
 
10 Discussion 
Pembrolizumab (Keytruda®) was approved by the EMA in July 2015 as mono-
therapy for the treatment of adults with advanced (unresectable or metastatic) 
melanoma [2]. The FDA granted accelerated approval for pembrolizumab in 
June 2015 for the treatment of patients with unresectable or metastatic mel-
anoma and disease progression following ipilimumab (and, if BRAF V600 
mutation positive, a BRAF inhibitor) [5]. 
KEYNOTE-006 [17], a randomised, open-label phase III study, was conduct-
ed to compare two different dosage regimens of pembrolizumab with ipili-
mumab in patients with advanced melanoma. Results showed a significant 
increase in PFS in patients who received pembrolizumab; patients achieved 
a gain of 2.7 months and 1.3 months in median PFS receiving pembrolizumab 
every 2 weeks and every 3 weeks compared to ipilimumab respectively. 12-
month OS was also improved among patients who received pembrolizumab: 
74.1% (pembrolizumab every 2 weeks) and 68.4% (pembrolizumab every 3 
weeks) compared to 58.2% of patients in the ipilimumab group. Response rates 
were also higher among patients who received pembrolizumab: 33.7 (pem-
brolizumab every 2 weeks) and 32.9% (pembrolizumab every 3 weeks) versus 
11.9% in ipilimumab-group patients.  
numerous  
phase II trials 
approved by EMA and 
FDA for patients with 
advanced melanoma 
KEYNOTE-006: 
improvement in PFS,  
OS and ORR in patients 
receiving 
pembrolizumab 
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However, it is notable that efficacy results of the KEYNOTE-006 trial are 
based on an interim analysis. Generally, the trial provides only results from 
a short duration of pembrolizumab exposure (ranging from 151-164 days) and, 
additionally, the trial has been terminated early. In this respect, the results of 
NCT02083484, an expanded access programme of pembrolizumab in patients 
with metastatic melanoma with limited to no treatment options, will be of in-
terest. Furthermore, PFS and response rates are surrogate parameters and OS 
results from KEYNOTE-006 were estimates from interim analyses.  
Treatment-related AEs of grade 3-5 were more frequent in ipilimumab-group 
patients compared to patients in the pembrolizumab groups. In terms of AEs 
of special interest (autoimmune and immune-related), hypothyroidism and hy-
perthyroidism were most frequent in the pembrolizumab groups. However, 
these side-effects are easier to be treated than immune-related gastrointestinal 
reactions such as colitis which are associated with ipilimumab therapy [22]. 
Generally, pembrolizumab provides a new option for the treatment of patients 
with advanced melanoma, showing higher response rates as compared to the 
standard treatment options ipilimumab and chemotherapy. In KEYNOTE-
006 and KEYNOTE-002, a significant improvement in PFS was observed 
among patients who had received pembrolizumab compared to patients in the 
control group receiving ipilimumab and chemotherapy respectively [17, 19]. 
Although these improvements were statistically significant, it does not nec-
essarily follow that they are clinically meaningful too.  
In the KEYNOTE-006 trial [17], two different schedules of pembrolizumab 
were assessed: 10 mg/kg, administered either every 2 or every 3 weeks; in the 
KEYNOTE-002 study [20], pembrolizumab was administered at a dose of 
2 mg/kg or 10 mg/kg every 3 weeks. In the dose-comparison cohort of KEY-
NOTE-001 [19], pembrolizumab 2 mg/kg was compared to 10 mg/kg every 3 
weeks. Among these three trials, the results were similar in efficacy and safety 
between the pembrolizumab groups. Both the EMA and the FDA recommend 
the administration of pembrolizumab at a dose of 2 mg/kg every 3 weeks [2, 
5]. This raises the question if, using the recommended (lower) dose, a com-
parative study of pembrolizumab and ipilimumab would show the same effi-
cacy and safety results as reported from KEYNOTE-006. Nevertheless, there is 
no phase III data for a direct comparison of pembrolizumab 2 mg/kg or 10 mg/ 
kg administered every 3 weeks. In trials evaluating pembrolizumab for other 
types of cancer including non-small-cell lung cancer, genitourinary cancers 
or head and neck squamous-cell carcinoma, different dosages (ranging from 
1 mg/kg to 10 mg/kg) were administered in different schedules [23]. However, 
pembrolizumab is not licensed for any of these cancers and no conclusions can 
be drawn from these trials. At any rate, the administration of a higher dose 
(>2 mg/kg every 3 weeks) of pembrolizumab would significantly increase the 
costs of pembrolizumab treatment. 
In the past decade, various targeted therapies, including kinase inhibitors, 
immune activators and, subsequent combination regimens, have become avail-
able for melanoma patients [24, 25]. Several targeted agents have been ap-
proved by the EMA and the FDA in the past few years for melanoma treat-
ment: vemurafenib, dabrafenib as monotherapy (EMA and FDA) and in com-
bination with trametinib (FDA only), ipilimumab and, most recently, nivo-
lumab and pembrolizumab. It is notable that both nivolumab and pembroli-
zumab are PD-1-blocking antibodies approved for the same melanoma indi-
cation: the treatment of patients with unresectable or metastatic melanoma 
and disease progression following ipilimumab and, if BRAF V600 mutation 
efficacy results of 
KEYNOTE-006 based on 
an interim analysis 
grade 3-5  
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are significant  
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positive, a BRAF inhibitor [5, 26]. Due to this short clinical experience (as 
compared to standard – chemotherapeutical – treatment options, e.g. dacarba-
zine), there is a lack of long-term data on these new agents; even the KEY-
NOTE-006 trial has been stopped earlier than planned. A central tenet of 
immunotherapy, the long-lasting benefit, is as yet unproven for pembrolizu-
mab [27]. Especially regarding the impact of pembrolizumab on the immune 
system and the associated immune-related AEs, long-term data is required. 
Another unresolved issue of pembrolizumab treatment relates to the appro-
priate line of therapy: in the KEYNOTE-006 trial, more than two thirds of pa-
tients did not receive any prior line of therapy and pembrolizumab was their 
first-line therapy for advanced disease [17]. While the EMA approved pem-
brolizumab as monotherapy for advanced melanoma without any restrictions, 
the FDA granted marketing authorisation for patients with advanced disease 
and disease progression following ipilimumab and, if appropriate, a BRAF in-
hibitor. The approvals are based on different trials: the EMA approval is sup-
ported by evidence from KEYNOTE-002, KEYNOTE-006 and KEYNOTE-
001 [28]; the FDA only refers to phase II data from the dose-comparison co-
hort and a subgroup of KEYNOTE-001 [5]. This raises the question whether 
pembrolizumab should be administered as first- or second-line treatment of 
advanced melanoma. According to the ESMO [14], the recommendations for 
the first-line treatment of metastatic melanoma are “under debate”. Ipilimu-
mab has been the standard treatment in patients with BRAF wild-type dis-
ease; however, the results of KEYNOTE-006 indicate that anti-PD-1 antibody 
therapy is the preferred first-line treatment for patients with BRAF wild-type 
disease [17]. However, anti-PD-1 antibody therapies are also recommended 
as second-line treatment of advanced disease after ipilimumab failure [14]. 
This recommendation is supported by the results of the KEYNOTE-002 trial 
[20] where all patients had received prior ipilimumab, and PFS and overall 
response were improved in patients receiving pembrolizumab compared those 
who received chemotherapy. Robert et al. [19] showed that pembrolizumab is 
an effective treatment option in patients who are refractory to ipilimumab, 
providing an option for patients without other therapeutic options. However, 
the decision for the appropriate first-line therapy of advanced melanoma pa-
tients, regarding the use of either BRAF/MEK combination therapy or a PD-
1/PD-L1 antibody is influenced by disease burden, the presence of symptoms 
and serum lactate dehydrogenase (LDH) until predictive biomarkers (e.g. PD-1 
expression on the tumour) are identified and integrated into clinical practice 
[27].  
Furthermore, BRAF V600 mutation status needs to be clarified: in the KEY-
NOTE-006 study, BRAF V600 mutation status (mutations were observed in 
36.2% of patients) did not seem to influence the benefit of pembrolizumab 
over ipilimumab [17]. Results from an expanded access programme with 855 
participating patients also suggest the effectiveness and safety of immuno-
therapy (ipilimumab) in pretreated melanoma patients regardless of their 
BRAF status [29]. Since vemurafenib (Zelboraf®), a kinase inhibitor, is ap-
proved by both the EMA and the FDA for the treatment of BRAF V600 muta-
tion-positive, unresectable or metastatic melanoma [30, 31], it may be an ap-
propriate comparator to pembrolizumab in patients with BRAF V600 muta-
tion. However, the role of BRAF V600 mutation status and the optimal se-
quence of BRAF/MEK therapy and immunotherapy need to be defined.  
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With regard to the high costs of available immunotherapeutic agents, it is im-
portant to identify predictive biomarkers to select appropriate patients [32]; 
and it is necessary to explore the use of biomarkers to identify the patients 
most likely responding to monotherapy [33]. In this context, PD-L1 expres-
sion is currently under investigation. Merelli et al. [34] point out that most of 
the published data regarding PD-L1 expression, variability in the assays, cell 
immunolocalisation and cut-off values for positive vs. negative PD-L1 im-
munohistochemical expression are heterogeneous. They also report that PD-
L1 expression has been evaluated in primary tumours and metastatic tissue 
samples but that there is conflicting data concerning the PD-L1 and PD-1 ex-
pression in tissues from primary melanomas and respective metastases [34]. 
An important issue to be discussed are the high costs of immunotherapies, es-
pecially considering that not all patients respond to the therapy. According to 
expert information, pembrolizumab – in clinical practice – is administered for 
2 years in patients who respond to the therapy. In the KEYNOTE-006 trial, 
the longest possible pembrolizumab treatment duration was 2 years [17]. For 
one year of treatment, the costs of the comparators used in KEYNOTE-006, 
pembrolizumab and ipilimumab are similar (about € 90,000). However, de-
pending on the treatment duration of pembrolizumab and foremost depend-
ing on the actual dosage delivered, the costs for pembrolizumab can be con-
siderably higher. 
As a large number of patients is refractory to ipilimumab, pembrolizumab 
offers a new therapeutic option for these patients based on phase II studies. 
For these patients, chemotherapy is the only currently available option and 
fewer AEs were observed with pembrolizumab by comparison with chemo-
therapy. However, for patients who were previously untreated, the situation 
is less clear, especially since relevant issues including the role of BRAF status 
und the optimal dosage and schedule of pembrolizumab administration re-
main unclear. However, phase III long-term data is required to confirm the 
effectiveness and safety of pembrolizumab. Furthermore, biomarkers must 
be identified to define the appropriate patient population, not least in light 
of the high costs of pembrolizumab therapy.  
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